TY - JOUR
T1 - Children with hepatitis B virus infections, Democratic Republic of the Congo
AU - Morgan, Camille E.
AU - Powers, Kimberley A.
AU - Edwards, Jess K.
AU - Devkota, Upasana
AU - Biju, Stane
AU - Lin, Fengchang
AU - Schmitz, John L.
AU - Cloherty, Gavin
AU - Muwonga, Jérémie
AU - Mboyo, Aimée
AU - Tshiamala, Pascal
AU - Kashamuka, Melchior M.
AU - Tshefu, Antoinette
AU - Emch, Michael
AU - Yotebieng, Marcel
AU - Becker-Dreps, Sylvia
AU - Parr, Jonathan B.
AU - Thompson, Peyton
N1 - Publisher Copyright:
© 2025 The authors; licensee World Health Organization.
PY - 2025
Y1 - 2025
N2 - Objective To characterize childhood hepatitis B virus (HBV) epidemiology to inform elimination efforts in the Democratic Republic of the Congo, one of the most populous African countries. Methods Using the most recent (2013–2014) nationally representative Demographic and Health Survey, we analysed hepatitis B surface antigen (HBsAg) on dried blood spots and associated survey data from children aged 6–59 months. We estimated HBsAg-positivity prevalence nationally, regionally and by potential correlates of infection. We evaluated spatial variation in HBsAg-positivity prevalence overall, and by age, sex and vaccination status. Findings Using data representing 5773 children, we observed a national HBsAg-positivity prevalence of 1.3% (73/5773; 95% confidence interval, CI: 0.9 to 1.7), ranging from 0.0% in Kinshasa to 5.6% in Sud-Ubangi. Prevalence among boys (1.8%; 95% CI: 1.2 to 2.7) was double that among girls (0.7%; 95% CI: 0.4 to 1.3). Testing negative for tetanus antibodies, rural residence and poorer household were associated with higher HBsAg-positivity prevalence. We observed no difference in prevalence by age. Children had higher HBsAg-positivity odds if living with one or more HBsAg-positive adult household member (odds ratio, OR: 2.3; 95% CI: 0.7 to 7.8), particularly an HBsAg-positive mother (OR: 7.2; 95% CI: 1.6 to 32.3). Notably, nearly two thirds (36/51) of HBsAg-positive children had a HBsAg-negative mother. Conclusion Our investigation highlights the importance of subnational prevalence estimates in large countries such as the Democratic Republic of the Congo, and we have identified regions that may benefit from improved childhood vaccination delivery strategies and community HBV prevention efforts.
AB - Objective To characterize childhood hepatitis B virus (HBV) epidemiology to inform elimination efforts in the Democratic Republic of the Congo, one of the most populous African countries. Methods Using the most recent (2013–2014) nationally representative Demographic and Health Survey, we analysed hepatitis B surface antigen (HBsAg) on dried blood spots and associated survey data from children aged 6–59 months. We estimated HBsAg-positivity prevalence nationally, regionally and by potential correlates of infection. We evaluated spatial variation in HBsAg-positivity prevalence overall, and by age, sex and vaccination status. Findings Using data representing 5773 children, we observed a national HBsAg-positivity prevalence of 1.3% (73/5773; 95% confidence interval, CI: 0.9 to 1.7), ranging from 0.0% in Kinshasa to 5.6% in Sud-Ubangi. Prevalence among boys (1.8%; 95% CI: 1.2 to 2.7) was double that among girls (0.7%; 95% CI: 0.4 to 1.3). Testing negative for tetanus antibodies, rural residence and poorer household were associated with higher HBsAg-positivity prevalence. We observed no difference in prevalence by age. Children had higher HBsAg-positivity odds if living with one or more HBsAg-positive adult household member (odds ratio, OR: 2.3; 95% CI: 0.7 to 7.8), particularly an HBsAg-positive mother (OR: 7.2; 95% CI: 1.6 to 32.3). Notably, nearly two thirds (36/51) of HBsAg-positive children had a HBsAg-negative mother. Conclusion Our investigation highlights the importance of subnational prevalence estimates in large countries such as the Democratic Republic of the Congo, and we have identified regions that may benefit from improved childhood vaccination delivery strategies and community HBV prevention efforts.
UR - https://www.scopus.com/pages/publications/105008749314
UR - https://www.scopus.com/pages/publications/105008749314#tab=citedBy
U2 - 10.2471/BLT.24.292013
DO - 10.2471/BLT.24.292013
M3 - Article
C2 - 40511401
AN - SCOPUS:105008749314
SN - 0042-9686
VL - 103
SP - 354
EP - 365
JO - Bulletin of the World Health Organization
JF - Bulletin of the World Health Organization
IS - 6
ER -